| CASE REPORT |
|
| Year : 2020 | Volume
: 7
| Issue : 2 | Page : 78-81 |
|
|
A case of small-cell lung cancer harboring an epidermal growth factor receptor mutation that responded to epidermal growth factor receptor tyrosine kinase inhibitor treatment
Ching- Fu Chang1, Chih- We Wang2, Cheng- Lung Hsu1
1 Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
2 Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
Correspondence Address:
Dr. Cheng- Lung Hsu
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, No. 5, Fu-Hsing Street, Kwei-Shan, Taoyuan
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_31_19
|
|
|
Epidermal growth factor receptor (EGFR) mutations are extremely rare in small-cell lung cancer (SCLC), and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in SCLC is unclear. Herein, we present a case with SCLC harboring an EGFR mutation who also responded to a second-generation EGFR TKI (afatinib).
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
